Hepatosplenic Hodgkin lymphoma without lymphadenopathy following reversible methotrexate-associated lymphoproliferative disorder

References

• Thomas E, Brewster DH, Black RJ, Macfarlane GJ. Risk of malignancy among patients with rheumatic conditions. Int J Cancer. 2000;88(3):497–502.
   PubMed Web of Science ®Google Scholar
• Ekström K, Hjalgrim H, Brandt L, Baecklund E, Klareskog L, Ekbom A, et al. Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives. Arthritis Rheum. 2003;48(4):963–70.
   PubMed Web of Science ®Google Scholar
• Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum. 2004;50(6):1740–51.
   PubMed Web of Science ®Google Scholar
• Wong AK, Kerkoutian S, Said J, Rashidi H, Pullarkat ST. Risk of lymphoma in patients receiving antitumor necrosis factor therapy: a meta-analysis of published randomized controlled studies. Clin Rheumatol. 2012;31(4):631–6.
   PubMed Web of Science ®Google Scholar
• Baecklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 2006;54(3):692–701.
   PubMed Web of Science ®Google Scholar
• Gaulard P, Swerdlow SH, Harris NL, Jaffe ES, Sundstrom C. Other iatrogenic immunodeficiency-associated lymphoproliferative disorders. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., editors. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, vol., 4th edn. IARC: Lyon; 2008. pp.350–351.
   Google Scholar
• Freeman JL, Jafri SZ, Roberts JL, Mezwa DG, Shirkhoda A. CT of congenital and acquired abnormalities of the spleen. Radiographics. 1993;13(3):597–610.
   PubMed Web of Science ®Google Scholar
• O’Connell MJ, Schimpff SC, Kirschner RH, Abt AB, Wiernik PH. Epithelioid granulomas in Hodgkin disease. A favorable prognostic sign? JAMA. 1975;233(8):886–9.
   PubMed Web of Science ®Google Scholar
• Loo EY, Medeiros LJ, Aladily TN, Hoehn D, Kanagal-Shamanna R, Young KH, et al. Classical Hodgkin lymphoma arising in the setting of iatrogenic immunodeficiency: a clinicopathologic study of 10 cases. Am J Surg Pathol. 2013;37(8):1290–7.
   PubMed Web of Science ®Google Scholar
• Komatsuda A, Wakui H, Nimura T, Sawada K. Reversible infliximab-related lymphoproliferative disorder associated with Epstein-Barr virus in a patient with rheumatoid arthritis. Mod Rheumatol. 2008;18(3):315–8.
   PubMed Web of Science ®Google Scholar
• Mo N, Muthu S, O’Sullivan M. Regression of lymphoma after withdrawal of infliximab alone in an infliximab/methotrexate-treated RA patient. Rheumatology. 2011;50(4):808–10.
   PubMed Web of Science ®Google Scholar
• Feng WH, Cohen JI, Fischer S, Li L, Sneller M, Goldbach-Mansky R, et al. Reactivation of latent Epstein-Barr virus by methotrexate: a potential contributor to methotrexate-associated lymphomas. J Natl Cancer Inst. 2004;96(22):1691–702.
   PubMedGoogle Scholar
• Genestier L, Paillot R, Fournel S, Ferraro C, Miossec P, Revillard JP. Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. J Clin Invest. 1998;102(2): 322–8.
   PubMed Web of Science ®Google Scholar
• Mariette X, Cazals-Hatem D, Warszawki J, Liote F, Balandraud N, Sibilia J; Investigators of the Club Rhumatismes et Inflammation. Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood. 2002; 99(11):3909–15.
   PubMed Web of Science ®Google Scholar
• Hoshida Y, Xu JX, Fujita S, Nakamichi I, Ikeda J, Tomita Y, et al. Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication. J Rheumatol. 2007;34(2):322–31.
   PubMed Web of Science ®Google Scholar
• Ichikawa A, Arakawa F, Kiyasu J, Sato K, Miyoshi H, Niino D, et al. Methotrexate/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression. Eur J Haematol. 2013;91(1):20–8.
   PubMed Web of Science ®Google Scholar
• Moseley AC, Lindsley HB, Skikne BS, Tawfik O. Reversible methotrexate associated lymphoproliferative disease evolving into Hodgkin's disease. J Rheumatol. 2000;27(3):810–3.
   PubMed Web of Science ®Google Scholar
• Oyama T, Ichimura K, Suzuki R, Suzumiya J, Ohshima K, Yatabe Y, et al. Senile EBV+ B-cell lymphoproliferative disorders: a clinicopathologic study of 22 patients. Am J Surg Pathol. 2003; 27(1):16–26.
   PubMed Web of Science ®Google Scholar
• Guermazi A, Brice P, de Kerviler E E, Fermé C, Hennequin C, Meignin V, et al. Extranodal Hodgkin disease: spectrum of disease. Radiographics. 2001;21(1):161–79.
   PubMed Web of Science ®Google Scholar
• Munker R, Stengel A, Stäbler A, Hiller E, Brehm G. Diagnostic accuracy of ultrasound and computed tomography in the staging of Hodgkin's disease. Verification by laparotomy in 100 cases. Cancer. 1995;76(8):1460–6.
   PubMed Web of Science ®Google Scholar
• Adler S, Parthasarathy KL, Bakshi SP, Stutzman L. Gallium-67-citrate scanning for the localization and staging of lymphomas. J Nucl Med. 1975;16(4):255–60.
   PubMed Web of Science ®Google Scholar
• Vardareli E, Dündar E, Aslan V, Gülbaş Z. Acute liver failure due to Hodgkin's lymphoma. Med Princ Pract. 2004;13(6):372–4.
   PubMed Web of Science ®Google Scholar
• Cervantes F, Briones J, Bruguera M, Font C, Grau JM, Rozman C, et al. Hodgkin's disease presenting as a cholestatic febrile illness: incidence and main characteristics in a series of 421 patients. Ann Hematol. 1996;72(6):357–60.
   PubMed Web of Science ®Google Scholar